Dexmedetomidine is under clinical development by IX Biopharma and currently in Phase I for Anxiety Disorders. According to GlobalData, Phase I drugs for Anxiety Disorders have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dexmedetomidine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexmedetomidine overview
Dexmedetomidine (IXB-120) is under development for the treatment of acute agitation in dementia. The drug candidate is administered through sublingual route and acts by targeting alpha 2 adrenergic receptors. It is being developed based on WaferiX platform technology.
IX Biopharma overview
iX Biopharma discovers, develops and commercializes novel therapies to treat diseases targeting central nervous system. The company’s products include a Wafesil and Silcap, asublingual sildenafil wafer and Silcap. iX Biopharma provides pipeline products such as Wafermine, a sublingual ketamine oral wafer used to manage moderate to severe pain and pioid analgesia, Xativa, a sublingual wafer containing cannabidiol (CBD) against anxiety, movement disorder and chronic inflammation condition, dexmedetomidine wafer for the treatment of dementia related agitation and other indications. iX Biopharma utilizes its proprietary formulation Waferix Sublingual to develop its products. iX Biopharma is headquartered in Singapore.
For a complete picture of Dexmedetomidine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
